Industry News

Industry News

Better End Of Life Quality Of Life For Cancer Patients

Jul 10, 2012

In many cases, when cancer patients are left with no further options to treat their disease, the focus shifts from prolonging life to promoting the quality of life (QOL) at the end of life (EOL). Now, researchers have identified factors that influence better QOL at EOL... Read More

Brain Tumors Traced To Stem Cells In Developing Brain

Jul 10, 2012

Stem cells that come from a specific part of the developing brain help fuel the growth of brain tumors caused by an inherited condition, researchers at Washington University School of Medicine in St. Louis report... Read More

News From The Journal Of Clinical Investigation: July 9, 2012

Jul 10, 2012

Breathing easy: keeping airways open Asthma is an increasingly common chronic disorder characterized by wheezing and shortness of breath. Symptoms are caused by excessive airway smooth muscle contraction; however mechanisms serving to keep airways open are not fully understood... Read More

Colorectal Cancer Risk Associated With Inflammatory Bowel Disease

Jul 10, 2012

Inflammatory bowel disease is caused by chronic inflammation , which leads to damage of the intestinal epithelium. Patients with inflammatory bowel disease have an elevated risk for developing colorectal cancer because of this chronic inflammation. In an effort to develop strategies to break the cycle of inflammation, Dr... Read More

Colorectal Cancer Risk Associated With Inflammatory Bowel Disease

Jul 10, 2012

Inflammatory bowel disease is caused by chronic inflammation , which leads to damage of the intestinal epithelium. Patients with inflammatory bowel disease have an elevated risk for developing colorectal cancer because of this chronic inflammation. In an effort to develop strategies to break the cycle of inflammation, Dr... Read More

Discovery Of Molecule In Immune System That Could Help Treat Melanoma

Jul 10, 2012

Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth... Read More

For Production Of Early T-Cell Progenitors, Transcription Factor Lyl-1 Is Critical

Jul 10, 2012

A transcription factor called Lyl-1 is necessary for production of the earliest cells that can become T-cells, critical cells born in the thymus that coordinate the immune response to cancer or infections, said a consortium of researchers led by those from Baylor College of Medicine in a report in the journal Nature Immunology... Read More

What Improves Quality Of Life For Dying Cancer Patients?

Jul 10, 2012

Patients with advanced cancer who are reaching the end of their lives have a better quality of life if they are not hospitalized, are not in an intensive care unit, are being visited by a pastor if they are hospitalized or in a clinic, can worry less, have the opportunity to meditate or pray, and have a therapeutic alliance with their doctor, say researchers from the Dana-Farbe... Read More

Genetic Test To Decide Whether Erbitux Works For Colon Cancer Patients Approved By FDA

Jul 09, 2012

Up until now, some colorectal cancer (CRC) patients and their doctors had no way of determining whether the drug Erbitux (cetuximab) would be a helpful treatment based on the absence of a KRAS gene mutation. On July 6, 2012, the United States Food and Drug Administration (FDA) approved the first genetic test to help doctors decide which colon cancer patients might respond well to cetuximab... Read More

Sanofi Cancels Heparin Substitute Semuloparin

Jul 09, 2012

The experimental drug Semuloparin which acts to prevent blood clots and was considered as an alternative to standard heparins, has been withdrawn by it's European based manufacturer Sanofi. They have announced today that they will no longer be seeking marketing approval for the experimental medication... Read More

Previous Page   Next Page